Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase 2 LOTIS-2 study

According to results from the phase 2 LOTIS-2 trial, loncastuximab tesirine—an anti-CD19 antibody conjugated to a pyrrolobenzodiazepine dimer—produced durable, long-term responses among patients with heavily pretreated DLBCL. At 7.8 months follow-up, 48.3% patients achieved an overall response, and 24.8% patients achieved complete response. Among patients with a complete response, median OS and PFS were not reached, with 24-month OS and PFS rates of 68.2% (95% CI: 50.0-81.0) and 72.5% (95% CI: 48.2-86.8), respectively.